4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain
16 July 2000. Related: Conference reports.
Intl Drug Resistance Workshop 4 Sitges 2000
Tenofovir (PMPA), defining cross-resistance profiles
16 July 2000. Related: Conference reports, Drug resistance.
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
16 July 2000. Related: Conference reports.
Added value of hydroxyurea or IL-2 to STIs remains uncertain
16 July 2000. Related: Conference reports.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
A warning on simplification strategies: not suitable for all
16 July 2000. Related: Conference reports.